Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $17
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $15 to $17.
Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $15 to $17.